(Alliance News) - Barclays PLC on Monday said Chief Executive Officer CS Venkatakrishnan will undergo treatment for non-hodgkin lymphoma, a type of cancer that affects the lymphatic system.

In a letter to colleagues, Venkatakrishnan, known as Venkat, said he will undergo treatment for 12 to 16 weeks in New York, as doctors said his condition is curable with their prescribed regimen.

During this period, he will "continue to be actively engaged" in managing the London-based bank, although he will work from home for some periods and will be unable to travel. 

"Fortunately, I have always exercised regularly and am strong and fit as I commence this treatment," he said. "I am very confident that we will continue, with your help, to serve our customers and clients well, and produce strong operating performance for our shareholders," the CEO said to colleagues.

Venkat took over as CEO of Barclays last November, after Jes Staley stepped down amid a probe by UK regulators into his description of his relationship with disgraced late financier Jeffery Epstein.

Barclays shares were up 0.6% to 159.94 pence on Monday morning in London.

By Jaskeet Briah; jaskeetbriah@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.